SM-27   Click here for help

GtoPdb Ligand ID: 14598

Compound class: Synthetic organic
Comment: SM-27 is a small molecule-drug conjugate (SMDC) [2]. It is made up of a ligand that targets aldo-keto reductase family 1 member C3 (AKR1C3) inside tumour cells, with a cathepsin B-cleavable linkage to the cytotoxic agent gemcitabine. The linker contains a valine-alanine dipeptide bridge that is specifically recognized and cleaved by cathepsin B (CTSB; which is highly expressed by tumour cells) [1,3]. SM-27 is intended to selectively deliver the chemotherapeutic to tumour cells, whilst reducing off-target or bystander toxicity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 16
Hydrogen bond donors 6
Rotatable bonds 19
Topological polar surface area 238.81
Molecular weight 811.79
XLogP 0.99
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)[C@@H](C(=O)N[C@@H](C)C(=O)NC1=NC(=O)N(C=C1)[C@H]2C([C@@H]([C@@H](CO)O2)O)(F)F)NC(=O)C3=CC(=CC(=C3)NC(=O)C4=C(C=CC=C4)OCC5=C(C)ON=C5C)OC
Isomeric SMILES CC([C@@H](C(N[C@H](C(NC=1C=CN(C(N1)=O)[C@@H]2O[C@@H]([C@H](C2(F)F)O)CO)=O)C)=O)NC(C3=CC(NC(C4=CC=CC=C4OCC5=C(ON=C5C)C)=O)=CC(OC)=C3)=O)C
InChI InChI=1S/C38H43F2N7O11/c1-18(2)30(35(53)41-20(4)32(50)43-29-11-12-47(37(54)44-29)36-38(39,40)31(49)28(16-48)57-36)45-33(51)22-13-23(15-24(14-22)55-6)42-34(52)25-9-7-8-10-27(25)56-17-26-19(3)46-58-21(26)5/h7-15,18,20,28,30-31,36,48-49H,16-17H2,1-6H3,(H,41,53)(H,42,52)(H,45,51)(H,43,44,50,54)/t20-,28+,30-,31+,36+/m0/s1
InChI Key MTEGMVHIFRAMCD-PGVMJHPASA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Jin C, Ei-Sagheer AH, Li S, Vallis KA, Tan W, Brown T. (2022)
Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
Angew Chem Weinheim Bergstr Ger, 134 (13): e202114016. [PMID:38505643]
2. Wang X, Guo C, Liu Y, Han B, Zhang L, Liu Z, Chen Y, Sun H. (2026)
Design, Synthesis, and Biological Evaluation of a Cathepsin B-Activated Small Molecule-Drug Conjugate Targeting AKR1C3 to Enhance Chemotherapeutic Selectivity.
J Med Chem, [Epub ahead of print]. [PMID:42470376]
3. Xiao D, Zhao L, Xie F, Fan S, Liu L, Li W, Cao R, Li S, Zhong W, Zhou X. (2021)
A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
Theranostics, 11 (6): 2550-2563. [PMID:33456559]